|
Significant Strategic Drug Development Collaborations - Additional Information (Detail) (USD $)
|
0 Months Ended | 12 Months Ended | 174 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jan. 23, 2014
Subsequent Event [Member]
|
Dec. 31, 2013
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
|
Dec. 31, 2012
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
|
Dec. 31, 2011
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
|
Jan. 30, 2014
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Subsequent Event [Member]
|
Dec. 31, 2013
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Forecast [Member]
|
Dec. 31, 2013
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Minimum [Member]
|
Dec. 31, 2013
Baxter Healthcare SA and Baxter Healthcare Corporation [Member]
Maximum [Member]
|
Dec. 31, 2013
SynBio LLC [Member]
|
Dec. 31, 2012
SynBio LLC [Member]
|
Dec. 31, 2013
Serum Institute of India Limited [Member]
|
Dec. 31, 2012
Serum Institute of India Limited [Member]
Product
|
Dec. 31, 2013
Serum Institute of India Limited [Member]
Development and Manufacturing Arrangement [Member]
|
Dec. 31, 2013
Serum Institute of India Limited [Member]
Minimum [Member]
|
Dec. 31, 2013
Serum Institute of India Limited [Member]
Maximum [Member]
|
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||||||||||||
| Research and development service fees recognized as revenue | $ 0 | $ 0 | $ 5,000,000 | ||||||||||||
| Supply agreement amended period | 2010-09 | ||||||||||||||
| Research and development recognized as revenue | 1,000,000 | 0 | 3,000,000 | ||||||||||||
| Percentage of royalties | 2.00% | 3.50% | 2.00% | 8.00% | |||||||||||
| Royalties expiration period | 10 years | ||||||||||||||
| Royalties expiration description | The Company's right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in that particular country. | ||||||||||||||
| Development receipts | 18,000,000 | ||||||||||||||
| Regulatory receipts | 16,000,000 | ||||||||||||||
| Sales target receipts | 66,000,000 | ||||||||||||||
| Company issued new shares of common stock value | 10,000,000 | 1,100,000 | |||||||||||||
| Agreement amended period | 2014-01 | ||||||||||||||
| Research and development supply service revenues | 0 | 100,000 | |||||||||||||
| Royalties receivable percentage | 10.00% | ||||||||||||||
| Royalties payment percentage | 10.00% | ||||||||||||||
| Share ownership percentage | 45.30% | 45.30% | 10.60% | 10.60% | |||||||||||
| Description and terms of license and arrangements | In the period from 2004 through 2011, the Company entered into and amended certain license and supply agreements with Serum Institute. The original license agreement with Serum Institute was a collaborative Development and Manufacturing Arrangement ("DMA") to develop agreed upon potential commercial product candidates using the Company's PolyXen technology. | ||||||||||||||
| Company issued new shares of common stock, Shares | 132,545,504 | 2,880,000 | |||||||||||||
| In-process research and development expense | 1,100,000 | ||||||||||||||
| Number of potential commercial product | 14 | ||||||||||||||
| License amendment description | Following the 2011 amendment, Serum Institute retained an exclusive license to use the Company’s PolyXen® technology to research and develop one potential commercial product, Polysialylated Erythropoietin (“PSA-EPO”). Serum Institute will be responsible for conducting all pre-clinical and clinical trials required to achieve regulatory approvals within the certain predetermined territories at Serum Institute’s own expense. The royalty payment schedule based on net revenues on the future commercial sales of PSA-EPO under the DMA was also modified as a result of the 2011 amendment. | ||||||||||||||
| Percentage of royalty payments of net sales | 25.00% | ||||||||||||||
| Royalty revenue or expense | 0 | 0 | |||||||||||||
| Milestone or other research-related payments due under the DMA | 0 | ||||||||||||||
| Common stock shares, subscribed | 800,000 | ||||||||||||||
| Common stock value, subscribed | $ 421,163 | ||||||||||||||